About ResMed Inc.
https://www.resmed.comResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service.
CEO
Michael J. Farrell BE, MBA, SM
Compensation Summary
(Year 2025)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2010-08-31 | Forward | 2:1 |
| 2005-10-03 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 758
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
UBS
Buy
Citigroup
Buy
RBC Capital
Outperform
Mizuho
Outperform
Keybanc
Overweight
Morgan Stanley
Overweight
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:19.04M
Value:$4.94B
BLACKROCK, INC.
Shares:12.28M
Value:$3.19B
BLACKROCK INC.
Shares:11.69M
Value:$3.03B
Summary
Showing Top 3 of 1,208
About ResMed Inc.
https://www.resmed.comResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $1.34B ▼ | $374.28M ▲ | $348.54M ▼ | 26.1% ▼ | $2.38 ▼ | $503.28M ▼ |
| Q4-2025 | $1.35B ▲ | $365.53M ▲ | $379.7M ▲ | 28.17% ▼ | $2.59 ▲ | $532.34M ▲ |
| Q3-2025 | $1.29B ▲ | $340.14M ▲ | $365.04M ▲ | 28.26% ▲ | $2.49 ▲ | $469.6M ▼ |
| Q2-2025 | $1.28B ▲ | $334.03M ▲ | $344.62M ▲ | 26.88% ▲ | $2.35 ▲ | $479.01M ▲ |
| Q1-2025 | $1.22B | $329.91M | $311.36M | 25.43% | $2.12 | $442.71M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $1.38B ▲ | $8.31B ▲ | $2.19B ▼ | $6.12B ▲ |
| Q4-2025 | $1.21B ▲ | $8.17B ▲ | $2.21B ▲ | $5.97B ▲ |
| Q3-2025 | $944.84M ▲ | $7.57B ▲ | $2.02B ▲ | $5.55B ▲ |
| Q2-2025 | $521.94M ▲ | $7.14B ▼ | $1.89B ▼ | $5.25B ▲ |
| Q1-2025 | $426.36M | $7.22B | $2.03B | $5.2B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $348.54M ▼ | $457.32M ▼ | $-52.58M ▲ | $-230.27M ▼ | $174.4M ▼ | $414.36M ▼ |
| Q4-2025 | $379.7M ▲ | $538.77M ▼ | $-133.71M ▼ | $-163.89M ▼ | $276.74M ▼ | $508.18M ▼ |
| Q3-2025 | $365.04M ▲ | $578.66M ▲ | $-31.79M ▲ | $-144.07M ▲ | $410.77M ▲ | $554.87M ▲ |
| Q2-2025 | $344.62M ▲ | $308.62M ▼ | $-36.69M ▼ | $-147.54M ▲ | $95.58M ▼ | $289.75M ▼ |
| Q1-2025 | $311.36M | $325.54M | $2.15M | $-150.76M | $188M | $305.93M |
Revenue by Products
| Product | Q4-2024 | Q2-2025 | Q1-2025 | Q1-2026 |
|---|---|---|---|---|
 Residential Care Software | $0 ▲ | $160.00M ▲ | $160.00M ▲ | $170.00M ▲ |
 Sleep And Respiratory | $1.07Bn ▲ | $1.13Bn ▲ | $1.07Bn ▼ | $1.17Bn ▲ |
 Software As Service | $150.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q3-2024 | Q1-2025 | Q2-2025 | Q1-2026 |
|---|---|---|---|---|
 Combined Europe Asia And Other Markets | $360.00M ▲ | $360.00M ▲ | $380.00M ▲ | $390.00M ▲ |
 Global | $0 ▲ | $160.00M ▲ | $160.00M ▲ | $170.00M ▲ |
 Us Canada And Latin America | $690.00M ▲ | $710.00M ▲ | $750.00M ▲ | $770.00M ▲ |
 Sleep And Respiratory | $150.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
CEO
Michael J. Farrell BE, MBA, SM
Compensation Summary
(Year 2025)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2010-08-31 | Forward | 2:1 |
| 2005-10-03 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 758
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
UBS
Buy
Citigroup
Buy
RBC Capital
Outperform
Mizuho
Outperform
Keybanc
Overweight
Morgan Stanley
Overweight
Grade Summary
Showing Top 6 of 11
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:19.04M
Value:$4.94B
BLACKROCK, INC.
Shares:12.28M
Value:$3.19B
BLACKROCK INC.
Shares:11.69M
Value:$3.03B
Summary
Showing Top 3 of 1,208